← Human Trials & Peer-Reviewed Studies
The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Plain-language guide to PMID 17214897 (2007): clinical trial of Vitamin D, K2, Magnesium and Zinc in 112 women, osteoporosis and bone density.
Key Facts
- PMID
- 17214897
- Journal
- BMC musculoskeletal disorders
- Year
- 2007
- Study type
- Clinical Trial
- Authors
- Deane A et al. (4 authors)
- DOI
- 10.1186/1471-2474-8-3
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density, published as a clinical trial.
The aims were to assess the impact of vitamin D status on changes in bone mineral density (BMD) in firstly patients with post-menopausal osteoporosis on bisphosphonates and secondly following discontinuation of bisphosphonates after long-term use.
Why It Was Studied
Moreover the maintenance of BMD after bisphosphonates withdrawal with the continuation of calcium/vitamin D supplements only, remains uncertain.
Who Took Part
The abstract describes 112 women taking part.
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
Two patient groups were recruited.
The first study population comprised of 112 women treated with a bisphosphonate.
How the Study Was Run
The second study population consisted of 35 women who had been on bisphosphonates for > 5 years in whom the treatment agent was discontinued.
Baseline BMD, changes in BMD following treatment, duration of treatment, serum 25 (OH) vitamin D, parathyroid hormone (PTH), urine C-terminal telopeptides of type 1 collagen (CTX) were obtained on the study participants.
What Was Measured
The subject headings attached to it are Bone Density, Bone Density Conservation Agents, Bone and Bones, Diphosphonates, Osteoporosis, Postmenopausal, Parathyroid Hormone and Substance Withdrawal Syndrome.
What This Means in Plain Language
This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 112 women in people with osteoporosis and bone density.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2007 (BMC musculoskeletal disorders), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.